
Aragen appoints Aniel Khubchandani as CEO of development and manufacturing solutions division
Ella Day | August 8, 2025 | Appointment | Manufacturing Services, Manufacturing and Production | Aragen Life Sciences, CEO, Corporate, development and manufacturing solutions, manufacturing services
Aragen Life Sciences, based in Hyderabad, India, has appointed Aniel Khubchandani as CEO of its development and manufacturing solutions (DMS) business. Khubchandani will also join the company’s management council.
Khubchandani has over 30 years of leadership experience in pharma and specialty chemicals. He previously served as CEO of Sekhmet Pharmaventures and joint-CEO at Jubilant Ingrevia Limited, with expertise spanning business transformation, strategic execution and commercial operations. He is a certified independent director and a Six Sigma Black Belt.
CEO of Aragen, Manni Kantipudi, commented: “Development and manufacturing solutions is a critical vertical with tremendous potential to significantly scale up. Aniel brings over 30 years of leadership experience to lead this journey.”
“I am excited to join Aragen and lead its development and manufacturing business,” said Khubchandani. “There’s an increasing focus on outsourcing, especially in the late phase and commercial manufacturing space, and the company is on the cusp of scaling to the next level of growth. I thank the board for giving me an opportunity to be a part of this exciting journey.”
Aragen operates six global sites and employs around 4,500 staff, providing research and development (R&D) and manufacturing services across the drug development pipeline.
Ella Day
8/8/25
Related Content

CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …

FibroGen rocked by unexpected death of CEO Thomas B Neff
In a saddening turn of events, San Francisco-based FibroGen has announced that Thomas B Neff, …

Allergan shareholders reject proposal to split roles of chairman and CEO
Allergan shareholders have rejected a proposal to immediately separate the roles of CEO and chairman, …






